Welcome, this website is intended for international healthcare professionals with an interest in the treatment of Advanced Prostate Cancer. By clicking the link below you are declaring and confirming that you are a healthcare professional

You are here

INTERVIEW WITH PROF. MILLER REGARDING ESMO 2013

Second interview with Mr. Miller

Summary from ESMO concerning prostate cancer: no advantages of ipilimumab in metastatic stage, enzalutamide in patients with hormone-sensitive PCA, interesting data on the combination of abiraterone and enzalutamide in castration resistant disease, new data on biomarkers.

The content of the videos, articles and all statements expressed therein do not necessarily reflect the opinions or views of the Editors, Authors or Reviewers of European Urology.